

UCSF

UC San Francisco Previously Published Works

Title

Amino Acid-Derived Sensors for Specific Zn<sup>2+</sup> Detection Using Hyperpolarized <sup>13</sup>C Magnetic Resonance Spectroscopy

Permalink

<https://escholarship.org/uc/item/02t2j4d0>

Journal

Chemistry - A European Journal, 25(51)

ISSN

0947-6539

Authors

Wang, Sinan

Korenchan, David E

Perez, Paola M

et al.

Publication Date

2019-09-12

DOI

10.1002/chem.201902771

Peer reviewed



# HHS Public Access

Author manuscript

*Chemistry*. Author manuscript; available in PMC 2020 September 12.

Published in final edited form as:

*Chemistry*. 2019 September 12; 25(51): 11842–11846. doi:10.1002/chem.201902771.

## Amino Acid-Derived Sensors For Specific Zn<sup>2+</sup> Detection Using Hyperpolarized <sup>13</sup>C Magnetic Resonance Spectroscopy

**Sinan Wang,**

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA 94107

**David E. Korenchan,**

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA 94107

**Paola M. Perez,**

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA 94107

**Céline Taglang,**

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA 94107

**Thomas R. Hayes,**

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA 94107

**Renuka Sriram,**

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA 94107

**Robert Bok,**

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA 94107

**Andrew S. Hong,**

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA 94107

**Yunkou Wu,**

Department of Radiology, Johns Hopkins University, Baltimore, MD, USA 21287

**Henry Li,**

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA 94107

**Zhen Wang,**

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA 94107

---

robert.flavell@ucsf.edu.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

**John Kurhanewicz,**

Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA 94107

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA 94107

**David M. Wilson,**

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA 94107


**Robert R. Flavell**

Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA 94107

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, USA 94107

**Abstract**

Alterations in  $Zn^{2+}$  concentration are seen in normal tissues and in disease states, and for this reason imaging of  $Zn^{2+}$  is an area of active investigation. Herein, enriched  $[1-^{13}C]$ cysteine and  $[1-^{13}C_2]$ iminodiacetic acid were developed as  $Zn^{2+}$ -specific imaging probes using hyperpolarized  $^{13}C$  magnetic resonance spectroscopy.  $[1-^{13}C]$ cysteine was used to accurately quantify  $Zn^{2+}$  in complex biological mixtures. These sensors can be employed to detect  $Zn^{2+}$  via imaging mechanisms including changes in  $^{13}C$  chemical shift, resonance linewidth, or  $T_1$ .

**Graphical abstract**

Enriched  $[1-^{13}C]$ cysteine and  $[1-^{13}C_2]$ iminodiacetic acid are developed as  $Zn^{2+}$ -specific imaging probes using hyperpolarized  $^{13}C$  magnetic resonance spectroscopy. These sensors can be employed to detect  $Zn^{2+}$  via imaging mechanisms including changes in  $^{13}C$  chemical shift, resonance linewidth, or  $T_1$ .  $[1-^{13}C]$ cysteine is able to accurately quantify  $Zn^{2+}$  in complex biological mixtures.

**Keywords**

imaging agents; zinc; hyperpolarization;  $^{13}C$  MRI; chemical shift

Zinc ( $Zn^{2+}$ ) is the second most abundant transition metal ion in the human body and plays various structural, regulatory and catalytic functions in physiology.<sup>1,2</sup> Multiple methods for

the measurement of  $Zn^{2+}$  concentration have been investigated as biomarkers for human disease, including blood and tissue tests, and imaging methods.<sup>3</sup> Existing imaging techniques include fluorescence and magnetic resonance-based approaches. Small-molecule fluorescent agents with varying  $Zn^{2+}$  affinities have been used to image live cells<sup>4,5,6</sup> Magnetic resonance imaging (MRI) using  $Zn^{2+}$ -responsive contrast agents has been proposed as an alternative imaging method that would allow non-invasive high-resolution monitoring of  $Zn^{2+}$  metabolism. Although there has been some success using manganese-derived probes<sup>7</sup> and paramagnetic chemical exchange saturation transfer agents,<sup>8</sup> most reported  $Zn^{2+}$ -responsive MRI agents are gadolinium-based.<sup>9,10</sup>

Enabled by hyperpolarization techniques such as dynamic nuclear polarization (DNP) and parahydrogen induced polarization (PHIP),<sup>11–14</sup> hyperpolarized (HP) probes for *in vivo* detection of a variety of analytes using HP  $^{13}C$  MRS have been developed.<sup>15,16</sup> Hyperpolarized EDTA and EGTA were reported for multi-metal imaging.<sup>17</sup> Here, we explored the use of HP  $^{13}C$  MRS for  $Zn^{2+}$ -specific imaging. In particular, we identified *L*-cysteine-1- $^{13}C$  ( $[1-^{13}C]Cys$ ) and iminodiacetic acid-1- $^{13}C_2$  ( $[1-^{13}C_2]IDA$ ) as candidate probes that demonstrate altered magnetic properties upon binding  $Zn^{2+}$ , optimized their polarization parameters, and demonstrated that  $[1-^{13}C]Cys$  can accurately measure  $Zn^{2+}$  using  $^{13}C$  HP MRS in phantoms and biological samples (Figure 1A).

We considered the requirements for a potential hyperpolarized  $Zn^{2+}$  imaging probe to include 1) a large change in  $^{13}C$  chemical shift in the presence of  $Zn^{2+}$ , 2) good selectivity to  $Zn^{2+}$  over biologically abundant cations such as  $Ca^{2+}$  and  $Mg^{2+}$ , 3) insensitivity to changes in pH over the physiologic range, 4) a sufficient  $T_1$  relaxation time for MRI, and 5) lack of known or predicted toxicity. We began our study by screening a variety of candidate  $Zn^{2+}$  ligands for their chemical shift response upon  $Zn^{2+}$  binding. Among the 34 tested compounds, 10 ligands demonstrated a chemical shift response to  $Zn^{2+}$  binding. We noted that ligands with logarithm of stability constants of  $Zn^{2+}$  ( $\log K$ ) greater than 6.9 all displayed a chemical shift response to  $Zn^{2+}$  binding, while ligands with  $\log K$  lower than 5.2 did not have a chemical shift response to  $Zn^{2+}$  binding (SI Table S1). Ligands bearing a soft functional group such as pyridine tended to show a chemical shift response at lower  $Zn^{2+}$  stability constants while ligands with hard functional groups, such as hydroxyl showed a chemical shift response at higher stability constants. Cysteine and iminodiacetic acid were selected for further evaluation because of their large chemical shift response to  $Zn^{2+}$  binding (+4.6 and +7.3 ppm in the presence of equimolar  $Zn^{2+}$ , respectively), excellent water solubility, low molecular weight, predicting a long  $^{13}C$   $T_1$ , and convenience for  $^{13}C$  labeling.  $^{13}C$ -labeled cysteine was commercially available, and  $^{13}C$ -labeled IDA was synthesized from  $[1-^{13}C]glycine$  and  $[1-^{13}C]methyl\ bromoacetate$  in 3 steps with a 32% total yield (Scheme 1). Their specificity for  $Zn^{2+}$  versus other abundant physiologic cations and their sensitivity to pH changes were also tested. Both probes showed excellent specificity for  $Zn^{2+}$  over other main physiologic cations  $Na^+$ ,  $K^+$ ,  $Ca^{2+}$  and  $Mg^{2+}$ , and limited chemical shift change over the physiologic pH range of 6.5 to 7.4 (Figure 1B). These preliminary investigations suggested that  $[1-^{13}C]Cys$  and  $[1-^{13}C_2]IDA$  would be specific and sensitive probes for detecting  $Zn^{2+}$  using HP  $^{13}C$  MRI.

A quantitative method for determining  $\text{Zn}^{2+}$  concentration was developed for these probes using NMR. A titration curve was plotted to show the chemical shift difference between  $[1-^{13}\text{C}]\text{Cys}$  and internal standard urea as a function of the  $\text{Zn}^{2+}$  to  $[1-^{13}\text{C}]\text{Cys}$  ratio. The peak moved linearly with increasing  $\text{Zn}^{2+}$  up to 0.25 equivalents of  $\text{Zn}^{2+}$  to  $[1-^{13}\text{C}]\text{Cys}$ . The rate of chemical shift change decreased at higher  $\text{Zn}^{2+}$  concentrations (Figure 2A, 2B, SI Table S2, SI equation S1). This suggests that  $[1-^{13}\text{C}]\text{Cys}$  may have multiple  $\text{Zn}^{2+}$  binding conformations, as previously reported.<sup>18,19</sup> The manifestation of the  $^{13}\text{C}$  signal as a single resonance indicates that the on-off rates for  $\text{Zn}^{2+}$  binding are rapid, compared with the absolute frequency difference between bound/unbound  $^{13}\text{C}$  resonances. A linewidth change with different  $\text{Zn}^{2+}/[1-^{13}\text{C}]\text{Cys}$  ratios was also observed. In particular, the linewidth increased significantly at lower  $\text{Zn}^{2+}$  concentrations with the widest linewidth being between 0.2 eq and 0.5 eq of  $[1-^{13}\text{C}]\text{Cys}$ , thus demonstrating exchange broadening at different  $\text{Zn}^{2+}/[1-^{13}\text{C}]\text{Cys}$  ratios (SI Table S3). The chemical shift change of  $[1-^{13}\text{C}]\text{Cys}$  with equimolar  $\text{Zn}^{2+}$  was tested at different temperatures ranging from 20 °C to 50 °C and at various  $[1-^{13}\text{C}]\text{Cys}$  concentrations from 1 mM to 100 mM. These studies showed that the temperature and concentration of  $[1-^{13}\text{C}]\text{Cys}$  (in the presence of equimolar zinc) had little or no influence on the chemical shift response (SI Tables S3 and S4).

A similar titration method was utilized for IDA for quantitative determination of  $\text{Zn}^{2+}$  concentration. When  $\text{Zn}^{2+}$  was added to  $[1-^{13}\text{C}_2]\text{IDA}$ , a new resonance at a lower field appeared. The area under the peak (integration) increased linearly with increasing  $\text{Zn}^{2+}$  concentration from 0 to 0.5 equivalents of  $\text{Zn}^{2+}$  to  $[1-^{13}\text{C}_2]\text{IDA}$ , which indicates that  $[1-^{13}\text{C}_2]\text{IDA}$  binds to  $\text{Zn}^{2+}$  with a 2:1 probe:Zn stoichiometry, as previously reported (Figure 2C, 2D).<sup>20</sup> Additionally, the unbound  $[1-^{13}\text{C}_2]\text{IDA}$  peak demonstrated increasing line broadening in response to  $\text{Zn}^{2+}$  (SI Table S5). It is worth noting that the  $[1-^{13}\text{C}_2]\text{IDA}:\text{Zn}$  complex appears as two separate peaks while the  $[1-^{13}\text{C}]\text{Cys}:\text{Zn}$  complex appears as a single peak, indicating that the on and off rates for  $[1-^{13}\text{C}_2]\text{IDA}$  are slower than the frequency difference between bound and unbound resonances and the on and off rates for  $[1-^{13}\text{C}]\text{Cys}$  are more rapid. These results are analogous to prior findings in  $^{15}\text{N}$ ,  $^{19}\text{F}$ , and hyperpolarized  $^{13}\text{C}$  pH imaging probe development efforts.<sup>21-27</sup> Overall, these data demonstrate that the chemical shift of the  $^{13}\text{C}$  NMR signal of cysteine and IDA change in a predictable and quantitative manner in response to  $\text{Zn}^{2+}$  concentration.

Next, we developed and optimized a hyperpolarization method for  $^{13}\text{C}$  labeled  $[1-^{13}\text{C}]\text{Cys}$  and  $[1-^{13}\text{C}_2]\text{IDA}$ . For  $[1-^{13}\text{C}]\text{Cys}$ , the optimized preparation was obtained by a mixture of 1.0 eq of  $[1-^{13}\text{C}]\text{Cys}$ , 0.5 eq of 4N HCl and 2.65 eq of glycerol, with 20 mM OX063 radical.<sup>28</sup> Using this method,  $13.4 \pm 0.6\%$  back-calculated polarization was obtained with a polarization time constant of  $1227 \pm 30$  (n = 3). The  $T_1$  relaxation time was  $36.0 \pm 1.8$  seconds at a magnetic field of 3T. A  $\text{Zn}^{2+}$ -dependent decrease in  $T_1$  of  $[1-^{13}\text{C}]\text{Cys}$  was observed when polarized  $[1-^{13}\text{C}]\text{Cys}$  was mixed with various equivalents of  $\text{Zn}^{2+}$ . A  $T_1$  of 17.5 seconds was observed when 1 equivalent of  $\text{Zn}^{2+}$  was present (Table S6). For  $[1-^{13}\text{C}_2]\text{IDA}$ , the optimized preparation included a mixture of 1.0 eq of  $[1-^{13}\text{C}_2]\text{IDA}$  disodium salt, 14.0 eq of  $\text{D}_2\text{O}$  and 1.8 eq of DMSO, with 15 mM OX063.<sup>17</sup> Using this method,  $6.6 \pm 0.9\%$  (n = 3) back-calculated polarization was obtained with the polarization time constant of  $1480 \pm 38$  (n = 3). The  $T_1$  was  $39.3 \pm 1.0$  seconds at 3T. The  $T_1$  of both bound and unbound  $[1-^{13}\text{C}_2]\text{IDA}$  resonances were also  $\text{Zn}^{2+}$  dependent, with the  $T_1$

decreasing to 16.6 seconds when 1 eq of  $\text{Zn}^{2+}$  was present (Figure 3, SI Table S7). We hypothesize that the decrease in  $T_1$  is due to an increase in molecular weight of the complex.<sup>29</sup> The high percent polarization, and relatively long  $T_1$  of the  $\text{Zn}^{2+}$  ligands suggested feasibility for subsequent imaging experiments.

The ability of the probes to image  $\text{Zn}^{2+}$  concentration was tested using phantoms on a 3T MRI system. For cysteine, a copolarization method, as we have previously reported, was developed with  $[1\text{-}^{13}\text{C}]\text{urea}$  as a chemical shift standard.<sup>23</sup> A four-compartment phantom containing various  $\text{Zn}^{2+}$  concentrations in each compartment was prepared (Figure 4A, B). As in the thermal equilibrium measurements, a chemical shift change was observed in response to  $\text{Zn}^{2+}$  in the  $^{13}\text{C}$  cysteine spectrum. By using the best-fit linear model of chemical shift as a function of  $\text{Zn}^{2+}$  concentration (Figure 2B inset), hyperpolarized  $[1\text{-}^{13}\text{C}]\text{Cys}$  was able to accurately determine the concentration over the physiologically relevant range of 0.2 – 20 mM  $\text{Zn}^{2+}$ . At the highest tested  $\text{Zn}^{2+}$  concentration of 40 mM, a slight deviation was observed, possibly due to signal loss and/or line broadening.

A phantom imaging experiment to determine the sensitivity showed that HP  $[1\text{-}^{13}\text{C}]\text{Cys}$  can detect 200  $\mu\text{M}$  of  $\text{Zn}^{2+}$  when 4 mM of  $[1\text{-}^{13}\text{C}]\text{Cys}$  was present (Figure 4B). When hyperpolarized  $[1\text{-}^{13}\text{C}_2]\text{IDA}$  was tested in a phantom for  $\text{Zn}^{2+}$  imaging, the  $\text{Zn}^{2+}$  bound  $[1\text{-}^{13}\text{C}_2]\text{IDA}$  peak appeared when more  $\text{Zn}^{2+}$  was present. The line broadening of both the  $\text{Zn}^{2+}$  bound and unbound peaks of  $[1\text{-}^{13}\text{C}_2]\text{IDA}$  resulted in a loss of SNR between 0.2 eq  $\text{Zn}^{2+}$  and 0.3 eq  $\text{Zn}^{2+}$  (SI Figure S2). For this reason, accurate  $\text{Zn}^{2+}$  concentrations could not be obtained using this probe. Overall, these phantom experiments demonstrated that hyperpolarized  $[1\text{-}^{13}\text{C}]\text{Cys}$  is a sensitive and accurate  $\text{Zn}^{2+}$  biosensor over the physiologic range, while issues with line broadening and signal loss limit the applicability of  $[1\text{-}^{13}\text{C}_2]\text{IDA}$ .

Finally, we verified that HP  $[1\text{-}^{13}\text{C}]\text{Cys}$  could accurately determine  $\text{Zn}^{2+}$  concentration in biological samples (Figure 5) by comparing imaging results against a commercially available fluorescence based  $\text{Zn}^{2+}$  quantification kit. Rat serum and prostate extracts were selected as biological samples with low and high  $\text{Zn}^{2+}$  concentration, respectively. In these samples, the  $\text{Zn}^{2+}$  concentration was accurately measured at 0.1 and 1.9 mM, respectively. The HP and kit  $\text{Zn}^{2+}$  measurements agreed within 0.1 mM. In order to verify that the signal change in these samples represented a specific response to  $\text{Zn}^{2+}$ , additional tubes including serum spiked with exogenous  $\text{Zn}^{2+}$ , and a prostate sample with additional tris(2-pyridylmethyl)amine (TPA), a high-affinity and specific chelator, were investigated.<sup>30</sup> We found that the  $\text{Zn}^{2+}$  concentration was accurately measured in the spiked serum sample, and that the addition of the TPA to the prostate extract blocked the chemical shift change. These data confirm that  $\text{Zn}^{2+}$  is both necessary and sufficient to induce the chemical shift change in cysteine, and moreover that this probe accurately and specifically determines  $\text{Zn}^{2+}$  concentration in complex biological samples.

For future *in vivo* applications,  $[1\text{-}^{13}\text{C}]\text{Cys}$  in particular demonstrates both possible advantages and limitations compared against existing techniques. Owing to the short lifetime of the signal, it is unlikely that it would be internalized into cells in a time course reasonable to measure intracellular zinc concentration. Therefore, this method would likely be restricted

to extracellular space  $Zn^{2+}$  imaging. However, zinc can be secreted from tissues including pancreas and prostate in response to glucose treatment. For example, Sherry et al. have developed imaging methods to detect the release of  $Zn^{2+}$  ions from  $\beta$ -cells in response to high glucose,<sup>31</sup> as well as to differentiate between healthy and malignant prostate tissue in mouse models.<sup>32</sup> Such a model could be applied for initial *in vivo* testing of these probes. An additional limitation could be metabolic transformation, which could confound interpretation of spectroscopic data. Toxicity concerns are unlikely based on the known toxicology profile of cysteine.<sup>33</sup> The majority of  $Zn^{2+}$  imaging probes are gadolinium-based contrast agents, which face the concern of their deposition in brain and environment, a concern which would be avoided in this case.<sup>34</sup> A final potential benefit of this method is the broad range of zinc concentration in serum and other tissues, potentially enabling high image contrast. Overall, these preliminary data suggest both possibilities and limitations for future *in vivo* applications of these methods.

Taken together, these data demonstrate that  $[1-^{13}C]Cys$  and  $[1-^{13}C_2]IDA$  represent promising probes for imaging  $Zn^{2+}$  using hyperpolarized  $^{13}C$  MRI. The probes demonstrate large changes in signal and chemical shift in response to  $Zn^{2+}$ , excellent selectivity over other biologically relevant cations and changes in pH, favorable  $T_1$  and polarization parameters, and can be imaged in phantom experiments.  $[1-^{13}C]Cys$  accurately quantified  $Zn^{2+}$  concentration in biological samples at physiologically relevant concentrations. For this reason,  $[1-^{13}C]Cys$  is a particularly promising probe for future *in vivo* hyperpolarized magnetic resonance imaging of pathologies with alterations in  $Zn^{2+}$  homeostasis such as prostate cancer, neurodegenerative disease, and diabetes.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements


R.R.F. acknowledges a Howard S. Stern award of the Society of Abdominal Radiology, a David Blitzer Prostate Cancer Foundation Young Investigator Award, a Department of Defense Prostate Cancer Research Program Physician Research Training Award, and NIH R21 EB026012-01.

## References


- [1]. Kambe T, Tsuji T, Hashimoto A, Itsumura N, *Physiol. Rev.* 2015, 95, 749–784. [PubMed: 26084690]
- [2]. Vallee BL, Auld DS, *Acc. Chem. Res.* 1993, 26, 543–551.
- [3]. Costello LC, Franklin RB, *Mol. Cancer.* 2006, 5, 1–13. [PubMed: 16403226]
- [4]. Zhang XA, Hayes D, Smith SJ, Friedle S, Lippard SJ, *J. Am. Chem. Soc.* 2008, 130, 15788–15789. [PubMed: 18975868]
- [5]. Komatsu K, Kikuchi K, Kojima H, Urano Y, Nagano T, *J. Am. Chem. Soc.* 2005, 127, 10197–10204. [PubMed: 16028930]
- [6]. Tsien RY, *Nat. Cell Biol.* 2003, 16–21. [PubMed: 12511887]
- [7]. Zhang X, Lovejoy KS, Jasanoff A, Lippard SJ, *Proc. Natl. Acad. Sci.* 2007, 104, 10780–10785. [PubMed: 17578918]
- [8]. Trokowski R, Ren J, Kálmán FK, Sherry AD, *Angew. Chemie. Int. Ed.* 2005, 44, 6920–6923.
- [9]. Lo ST, Martins AF, Jordan VC, Sherry AD, *Isr. J. Chem.* 2017, 57, 854–886. [PubMed: 30319140]

- [10]. Esqueda AC, López JA, Andreu-de-Riquer G, Alvarado-Monzón JC, Ratnakar J, Lubag AJM, Sherry AD, De León-Rodríguez LM, *J. Am. Chem. Soc.* 2009, 131, 11387–11391. [PubMed: 19630391]
- [11]. Gram A, Hansson G, Hansson L, Lerche MH, Ardenkjær-larsen JH, Servin R, Thaning M, Golman K, 2003, 100, 10158–10163.
- [12]. Golman K, Axelsson O, Jo H, Månsson S, Olofsson C, Petersson JS, *Magn. Reson. Med.* 2001, 5, 1–5.
- [13]. Leunbach I, Mansson S, Petersson JS, Ardenkjaer-Larsen JH, Golman K, *Proc. Natl. Acad. Sci.* 2003, 100, 10435–10439. [PubMed: 12930896]
- [14]. Nikolaou P, Goodson BM, Chekmenev EY, *Chem. -A Eur. J.* 2015, 21, 3156–3166.
- [15]. Day SE, Kettunen MI, Gallagher FA, Hu DE, Lerche M, Wolber J, Golman K, Ardenkjaer-Larsen JH, Brindle KM, *Nat. Med.* 2007, 13, 1382–1387. [PubMed: 17965722]
- [16]. Bhattacharya P, Chekmenev EY, Reynolds WF, Wagner S, Zacharias N, Chan HR, Bünger R, Ross BD, *NMR Biomed.* 2011, 24, 1023–1028. [PubMed: 21538638]
- [17]. Mishra A, Pariani G, Oerther T, Schwaiger M, Westmeyer GG, *Anal. Chem.* 2016, 88, 10790–10794. [PubMed: 27766840]
- [18]. Shindo H, Brown TL, *J. Am. Chem. Soc.* 1965, 87, 1904–1909. [PubMed: 14290272]
- [19]. Li NC, Manning RA, *J. Am. Chem. Soc.* 1955, 77, 5225–5228.
- [20]. Ni LB, Zhang RH, Liu QX, Xia WS, Wang H, Zhou ZH, *J. Solid State Chem.* 2009, 182, 2698–2706. [PubMed: 20161370]
- [21]. Düwel S, Hundshammer C, Gersch M, Feurecker B, Steiger K, Buck A, Walch A, Haase A, Glaser SJ, Schwaiger M, Schilling F, *Nat. Commun.* 2017, 1–9. [PubMed: 28232747]
- [22]. Korenchan DE, Taglang C, Von Morze C, Blecha JE, Gordon JW, Sriram R, Larson PEZ, Vigneron DB, Vanbrocklin HF, Kurhanewicz J, Wilson DM, Flavell RR, *Analyst* 2017, 142, 1429–1433. [PubMed: 28322385]
- [23]. Flavell RR, Von Morze C, Blecha JE, Korenchan DE, Van Crielkinge M, Sriram R, Gordon JW, Chen H, Subramaniam S, Bok RA, Wang Z, Vigneron D, Larson P; Kurhanewicz J, Wilson DM, *Chem. Commun.* 2015, 51, 14119–14122.
- [24]. Gallagher FA, Kettunen MI, Day SE, Hu DE, Ardenkjær-Larsen JH, Zandt RI, Jensen PR, Karlsson M, Golman K, Lerche MH, Brindle KM, *Nature* 2008, 453, 940–943. [PubMed: 18509335]
- [25]. Jiang W, Lumata L, Chen W, Zhang S, Kovacs Z, Sherry AD, Khemtong C, *Sci. Rep.* 2015, 5, 9104. [PubMed: 25774436]
- [26]. Shchepin RV, Barskiy DA, Coffey AM, Theis T, Shi F, Warren WS, Goodson BM, Chekmenev EY, *ACS Sensors* 2016, 1, 640–644. [PubMed: 27379344]
- [27]. Shchepin RV, Goodson BM, Theis T, Warren WS, Chekmenev EY, *ChemPhysChem* 2017, 18, 1961–1965. [PubMed: 28557156]
- [28]. Jensen PR, Karlsson M, Meier S, Duus J, Lerche MH, *Chem. -A Eur. J.* 2009, 15, 10010–10012.
- [29]. Keshari KR, Wilson DM, *Chem. Soc. Rev.* 2014, 43, 1627–1659. [PubMed: 24363044]
- [30]. Huang Z, Zhang X, Bosch M, Smith SJ, Lippard SJ, *Metallomics* 2013, 5, 648–655. [PubMed: 23715510]
- [31]. Lubag AJM, De Leon-Rodriguez LM, Burgess SC, Sherry AD, *Proc. Natl. Acad. Sci.* 2011, 108, 18400–18405. [PubMed: 22025712]
- [32]. Preihs C, Zhang S, Lo ST, Chen S, Li WH, Clavijo Jordan MV, Lubag AJM, De Leon-Rodriguez LM, Rofsky NM, Sherry AD, *Proc. Natl. Acad. Sci.* 2016, 113, 5464–5471.
- [33]. Lewis RJ Sr (ed), *Sax's Dangerous Properties of Industrial Materials*, 11th Edition Wiley-Interscience, Wiley & Sons, Inc Hoboken, NJ 2004, p1059.
- [34]. Guo BJ, Yang ZL, Zhang LJ, *Front. Mol. Neurosci.* 2018, 11, 1–12. [PubMed: 29403353]






**Scheme 1.**  
Synthesis of [1-<sup>13</sup>C<sub>2</sub>]IDA disodium salt.




**Figure 1.**


Approach to specific detection of Zn<sup>2+</sup> via hyperpolarized magnetic resonance spectroscopy (A) Structures of [1-<sup>13</sup>C]Cys and [1-<sup>13</sup>C<sub>2</sub>]IDA. (B) Specificity of 50 mM [1-<sup>13</sup>C]Cys and [1-<sup>13</sup>C<sub>2</sub>]IDA for physiological cations (present at 1 equivalent). pH-dependence of chemical shift was measured at pH 7.4 and 6.5, the physiologically relevant extracellular range.




**Figure 2.** Response of  $[1-^{13}\text{C}]$ Cys and  $[1-^{13}\text{C}_2]$ IDA to  $\text{Zn}^{2+}$  can be detected by several magnetic resonance mechanisms. (A)  $^{13}\text{C}$  NMR Spectra for 50 mM  $[1-^{13}\text{C}]$ Cys with varying  $\text{Zn}^{2+}$  concentrations (B) Standard titration curve of  $[1-^{13}\text{C}]$ Cys in response to various  $\text{Zn}^{2+}$  concentrations. The insert shows the titration curve at low  $\text{Zn}^{2+}$  equivalents. (C) Spectra for 50 mM  $[1-^{13}\text{C}_2]$ IDA with various  $\text{Zn}^{2+}$  concentrations highlighting formation of a  $\text{Zn}^{2+}$  bound species, and increased linewidth upon  $\text{Zn}^{2+}$  binding. \* represents natural abundance citric acid peak (D) Standard titration curve of  $[1-^{13}\text{C}_2]$ IDA.



**Figure 3.** Dynamic  $^{13}\text{C}$  NMR spectra following polarization of  $[1-^{13}\text{C}]\text{Cys}$  (left) and  $[1-^{13}\text{C}_2]\text{IDA}$  (right). Pulse conditions were  $\text{TR} = 3\text{s}$ ,  $5^\circ$  hard pulses, 10 kHz spectral width, 30 timepoints, nominal spectral resolution = 0.5 Hz.



**Figure 4.** HP [1-<sup>13</sup>C]Cys accurately quantifies Zn<sup>2+</sup> concentration in phantom imaging experiments through use of chemical shift measurements. (A) Phantom imaging conducted using 40 mM [1-<sup>13</sup>C]Cys. (B) Phantom experiment conducted using 4 mM [1-<sup>13</sup>C]Cys, indicating high sensitivity for low concentrations of Zn<sup>2+</sup>.



**Figure 5.** Hyperpolarized  $[1-^{13}\text{C}]\text{Cys}$  phantom imaging experiment demonstrating accurate  $\text{Zn}^{2+}$  quantification in biological samples. Accurate detection of  $\text{Zn}^{2+}$  concentration in presence of exogenous  $\text{Zn}^{2+}$  and in the presence of  $\text{Zn}^{2+}$ -chelating TPA demonstrates specificity of the probe for  $\text{Zn}^{2+}$  over other endogenous analytes.